NCT00663832 - A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2011

Conditions

Prostate Cancer

Interventions

DRUG

LBH589 (i.v. panobinostat)

"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"

Trial Locations (9)

10021

Novartis Investigative Site, New York

20850

Novartis Investigative Site, Rockville

27710

Novartis Investigative Site, Durham

48201

Novartis Investigative Site, Detroit

63110

Novartis Investigative Site, St Louis

89135

Novartis Investigative Site, Las Vegas

97239

Novartis Investigative Site, Portland

V5Z 1L8

Novartis Investigative Site, Vancouver

L8V 5C2

Novartis Investigative Site, Hamilton